Comparative Pharmacology
Head-to-head clinical analysis: CENTRAX versus DORAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CENTRAX versus DORAL.
CENTRAX vs DORAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Binds to benzodiazepine site on GABA-A receptors, enhancing chloride ion influx and hyperpolarization of neurons, resulting in anxiolytic, sedative, and muscle relaxant effects.
GABAA receptor positive allosteric modulator; enhances the inhibitory effects of GABA by binding to benzodiazepine receptors, increasing chloride channel opening frequency.
10-30 mg orally, 3-4 times daily.
15-30 mg orally at bedtime, maximum 60 mg/day.
None Documented
None Documented
60-120 hours (mean 100 hours); long half-life leads to accumulation upon multiple dosing and prolonged sedation.
Terminal elimination half-life: 40-120 hours (long-acting benzodiazepine). Accumulation occurs with repeated dosing, especially in elderly or hepatic impairment.
Renal (primarily as glucuronide conjugates; <1% unchanged); biliary/fecal: minimal (less than 5%).
Renal (primarily as metabolites; <1% unchanged). Biliary/fecal: minor.
Category C
Category C
Benzodiazepine
Benzodiazepine